Delstrigo

Delstrigo is a once-daily, fixed-dose combination tablet containing doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg). It is indicated as a complete antiretroviral regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing at least 35 kg. The combination includes doravirine, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), alongside two nucleoside reverse transcriptase inhibitors (NRTIs), lamivudine and tenofovir disoproxil fumarate. These components work synergistically to inhibit the HIV-1 reverse transcriptase enzyme, thereby preventing the conversion of viral RNA into DNA and halting viral replication. Developed by Merck & Co., Delstrigo was approved by the FDA in 2018. The Chelsea and Westminster NHS Foundation Trust is specifically evaluating the drug in the Phase 4 META-D trial to assess its impact on metabolic parameters, such as lipids and body composition, when switching from integrase inhibitor-based therapies.

Brand names

Delstrigo

Other names

doravirine + lamivudine + tenofovir disoproxil fumarateDOR/3TC/TDFTDF/3TC/DOR